Overexpression of Rho GDP-dissociation inhibitor atpha is associated with tumor progression and poor prognosis of colorectal cancer

Journal of Proteome Research

Volumn 7, Issue 9, 2008, Pages 3994-4003

  Zhao, Liang ^a   Wang, Hui ^b   Li, Jianming ^a   Liu, Yawei ^a   Ding, Yanqing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Colorectal cancer; Metastasis; Poor prognosis; Proteomics; Rho GDP dissociation inhibitor alpha

Indexed keywords

GUANOSINE DIPHOSPHATE; RHO FACTOR; RHO GDP DISSOCIATION INHIBITOR ALPHA; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; PRIMER DNA; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS;

ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING; COLORECTAL TUMOR; DISEASE COURSE; FEMALE; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA PRIMERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL ANALYSIS;

EID: 55249087212     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800271b     Document Type: Article

References (50)

1. Tan, S.; Seow, T. K.; Liang, R. C.; Koh, S.; Lee, C. P.; Chung, M. C.; Hooi, S. C. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int. J. Cancer 2002, 98 (4), 523-31.
2. You, W. C.; Jin, F.; Devesa, S.; Gridley, G.; Schatzkin, A.; Yang, G.; Rosenberg, P.; Xiang, Y. B.; Hu, Y. R.; Li, Q. Rapid increase in colorectal cancer rates in urban Shanghai, 1972-97, in relation to dietary changes. J. Cancer Epidemiol. Prev. 2002, 7 (3), 143-6.
3. Li, S.; Wang, ]:, Lu, Y.; Fan, D. Screening and early diagnosis of colorectal cancer in China: a 12 year retrospect (1994-2006). J. Cancer Res. Clin. Oncol. 2007, 133 (10), 679-86.
4. Ridley, A. J. Rho GTPases and cell migration. J. Cell Sci. 2001, 114 (Pt 15), 2713-22.
5. Etienne-Manneville, S.; Hall, A. Rho GTPases in cell biology. Nature 2002, 420 (6916), 629-35.
6. Sahai, E.; Marshall, C. J. RHO-GTPases and cancer. Nat. Rev. Cancer 2002, 2 (2), 133-42.
7. Bishop, A. L.; Hall, A. Rho GTPases and their effector proteins. Biochem. J. 2000, 348 (Pt 2), 241-55.
8. Van Aelst, L.; D'Souza-Schorey, C. Rho GTPases and signaling networks. Genes Dev. 1997, 11 (18), 2295-322.
9. Hall, A. Rho GTPases and the Actin cytoskeleton. Science 1998, 279 (5350), 509-14.
10. Sun, Q.; Ding, Y. Q.; Gao, X. Q.; Yan, S.; Han, J. X. Development and application of cDNA microarray of tumor metastasis-associated genes. Diyi Junyi Daxue Xuebao 2002, 22 (12), 1070-5.
11. Huang, Z. X.; Sun, Q.; Ding, Y. Q.; Yao, K. T. Mining microarray gene expression data of metastatic colorectal cancer by literature profiling. Diyi Junyi Daxue Xuebao 2003, 23(11), 1195-7.
12. Weng, D. S.; Ding, Y. Q.; Sun, Q. Differences in gene expression profile between high and low metastatic human colorectal cancer cell lines. Diyi Junyi Daxue Xuebao 2004, 24 (3), 256-9.
13. Liu, L.; Zhang, Q.; Zhang, Y.; Wang, S.; Ding, Y. Lentivirus-mediated silencing of Tiaml gene influences multiple functions of a human colorectal cancer cell line. Neoplasia 2006, 8 (11), 917-24.
14. Liu, L.; Zhao, L.; Zhang, Y.; Zhang, Q.; Ding, Y. Proteomic analysis of Tiaml-mediated metastasis in colorectal cancer. Cell Biol. Int. 2007, 31 (8), 805-14.
15. Zhang, Y. F.; Liu, L.; Ding, Y. Q. Isolation and characterization of human colorectal cancer cell subline with unique metastatic potential in the liver. J. South Med. Univ. 2007, 27 (2), 126-30.
16. Zhao, L.; Liu, L.; Wang, S.; Zhang, Y. F.; Yu, L.; Ding, Y. Q. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J. Cancer Res. Clin. Oncol. 2007, 133 (10), 771-82.
17. Ramagli, L. S. Quantifying protein in 2-D PAGE solubilization buffers. Methods Mol. Biol. 1999, 112, 99-103.
18. Coppola, D.; Szabo, M.; Boulware, D.; Muraca, P.; Alsarraj, M.; Chambers, A. F.; Yeatman, T. J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004, I0 (1 Pt 1), 184-90.
19. Nobes, C. D.; Hall, A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81 (1), 53-62.
20. Faure, J.; Dagher, M. C. Interactions between Rho GTPases and Rho GDP dissociation inhibitor (Rho-GDI). Biochimie2001, 83 (5), 409-14.
21. DerMardirossian, C; Bokoch, G. M. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005, 15 (7), 356-63.
22. Ueda, T.; Kikuchi, A.; Ohga, N.; Yamamoto, J.; Takai, Y. Purification and characterization from bovine brain cytosol of a novel regulatory protein inhibiting the dissociation of GDP from and the subsequent binding of GTP to rhoB p20, a ras p21-like GTP-binding protein. J. Biol. Chem. 1990, 265 (16), 9373-80.
23. Fukumoto, Y.; Kaibuchi, K.; Hori, Y.; Fujioka, H.; Araki, S.; Ueda, T.; Kikuchi, A.; Takai, Y. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene 1990, 5 (9), 1321-8.
24. Lelias, J. M.; Adra, C. N.; Wulf, G. M.; Guillemot, J. C.; Khagad, M.; Caput, D.; Lim, B. cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc. Natl. Acad. Set U.S.A. 1993, 90 (4), 1479-83.
25. Scherle, P.; Behrens, T.; Staudt, L. M. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1993, 90 (16), 7568-72.
26. Adra, C. N.; Manor, D.; Ko, J. L.; Zhu, S.; Horiuchi, T.; Van Aelst, L.; Cerione, R. A.; Lim, B. RhoGDIgamma: a GDP-dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (9), 4279-84.
27. Zalcman, G.; Closson, V.; Camonis, J.; Honore, N.; Rousseau-Merck, M. F.; Tavitian, A.; Olofsson, B. RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J. Biol. Chem. 1996, 271 (48), 30366-74.
28. Golovanov, A. P.; Chuang, T. H.; DerMardirossian, C.; Barsukov, I.; Hawkins, D.; Badii, R.; Bokoch, G. M.; Lian, L. Y.; Roberts, G. C. Structure-activity relationships in flexible protein domains: regulation of rho GTPases by RhoGDI and D4 GDI. J. Mol. Biol. 2001, 305 (1), 121-35.
29. Hoffman, G. R.; Nassar, N.; Cerione, R. A. Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 2000, 100 (3), 345-56.
30. Grizot, S.; Faure, J.; Fieschi, F.; Vignais, P. V.; Dagher, M. C.; Pebay-Peyroula, E. Crystal structure of the Racl-RhoGDI complex involved in nadph oxidase activation. Biochemistry 2001, 40 (34), 10007-13.
31. Gildea, J. J.; Seraj, M. J.; Oxford, G.; Harding, M. A.; Hampton, G. M.; Moskaluk, C. A.; Frierson, H. F.; Conaway, M. R.; Theodorescu, D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002, 62 (22), 6418-23.
32. Jiang, W. G.; Watkins, G.; Lane, J.; Cunnick, G. H.; Douglas-Jones, A.; Mokbel, K.; Mansel, R. E. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin. Cancer Res. 2003, 9 (17), 6432-40.
33. Jones, M. B.; Krutzsch, H.; Shu, H.; Zhao, Y.; Liotta, L. A.; Kohn, E. C.; Petricoin, E. F., 3rd. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002, 2 (1), 76-84.
34. Kasper, B.; Tidow, N.; Grothues, D.; Welte, K. Differential expression and regulation of GTPases (RhoA and Rac2) and GDIs (LyGDI and RhoGDI) in neutrophils from patients with severe congenital neutropenia. Blood 2000, 95 (9), 2947-53.
35. Tian, T.; Hao, J.; Xu, A.; Hao, J.; Luo, C.; Liu, C.; Huang, L.; Xiao, X.; He, D. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007, 98 (8), 1265-74.
36. Olofsson, B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell. Signalling 1999, 11 (8), 545-54.
37. Dovas, A.; Couchman, J. R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem. J. 2005, 390 (Pt 1), 1-9.
38. Di-Poi, N.; Faure, J.; Grizot, S.; Molnar, G.; Pick, E.; Dagher, M. C. Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex. Biochemistry 2001, 40 (34), 10014-22.
39. Abo, A.; Pick, E.; Hall, A.; Totty, N.; Teahan, C. G.; Segal, A. W. Activation of the NADPH oxidase involves the small GTP-binding protein p21racl. Nature 1991, 353 (6345), 668-70.
40. Bromberg, Y.; Shani, E.; Joseph, G.; Gorzalczany, Y.; Sperling, O.; Pick, E. The GDP-bound form of the small G protein Racl p21 is a potent activator of the superoxide-forming NADPH oxidase of macrophages. J. Biol. Chem. 1994, 269 (10), 7055-8.
41. Lin, Q.; Fuji, R. N.; Yang, W.; Cerione, R. A. RhoGDI is required for Cdc42-mediated cellular transformation. Curr. Biol. 2003, 13 (17), 1469-79.
42. Arozarena, I.; Matallanas, D.; Crespo, P. Maintenance of CDC42 GDP-bound state by Rho-GDI inhibits MAP kinase activation by the exchange factor Ras-GRF. evidence for Ras-GRF function being inhibited by Cdc42-GDP but unaffected by CDC42-GTP. J. Biol. Chem. 2001, 276 (24), 21878-84.
43. Gandhi, P. N.; Gibson, R. M.; Tong, X.; Miyoshi, J.; Takai, Y.; Konieczkowski, M.; Sedor, J. R.; Wilson-Delfosse, A. L. An activating mutant of Racl that fails to interact with Rho GDP-dissociation inhibitor stimulates membrane ruffling in mammalian cells. Biochem. J. 2004, 378 (Pt 2), 409-19.
44. Zhang, B.; Zhang, Y.; Dagher, M. C.; Shacter, E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005, 65 (14), 6054-62.
45. MacKeigan, J. P.; Clements, C. M.; Lich, I. D.; Pope, R. M.; Hod, Y.; Ting, J. P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoG-Dlalpha. Cancer Res. 2003, 63 (20), 6928-34.
46. Jiang, D.; Ying, W.; Lu, Y.; Wan, J.; Zhai, Y.; Liu, W.; Zhu, Y.; Qiu, Z.; Qian, X.; He, F. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 2003, 3 (5), 724-37.
47. Alessandro, R.; Masiero, L.; Liotta, L. A.; Kohn, E. C. The role of calcium in the regulation of invasion and angiogenesis. In Vivo 1996, 10 (2), 153-60.
48. Takahashi, K.; Sasaki, T.; Mammoto, A.; Takaishi, K.; Kameyama, T.; Tsukita, S.; Takai, Y. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J. Biol. Chem. 1997, 272 (37), 23371-5.
49. Essmann, F.; Wieder, T.; Otto, A.; Muller, E. C.; Dorken, B.; Daniel, P. T. GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. Biochem. J. 2000, 346 (Pt 3), 777-83.
50. Sinha, P.; Kohl, S.; Fischer, J.; Hutter, G.; Kern, M.; Kottgen, E.; Dietel, M.; Lage, H.; Schnolzer, M.; Schadendorf, D. Identification of novel proteins associated with the development of chemore-sistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000, 21 (14), 3048-57.